NYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning after the Danish pharmaceutical giant posted ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog ...

Obesity drug developer Aardvark Therapeutics (AARD) has filed for a $100M initial public offering. Aardvark (AARD) didn't ...

LONDON – Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone and adding broader measurements such as heart health. The ...

The Lancet medical journal’s Diabetes & Endocrinology Commission last week proposed a new definition and method for diagnosing obesity, beyond simply looking at a person’s Body Mass Index (BMI), the ...

Copyright 2025 The Associated Press. All Rights Reserved. First lady Melania Trump, from second right, and President Donald Trump walk walk as former President Joe ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.